MNMD
Mind Medicine (MindMed) Inc.12.26
+0.18+1.49%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.19BP/E (TTM)
-Basic EPS (TTM)
-1.98Dividend Yield
0%Recent Filings
10-K
FY2025 results
Definium Therapeutics posted FY2025 results reflecting clinical-stage losses with no revenue disclosed in the 10-K, as it advances DT120 ODT through Phase 3 trials for GAD and MDD, including Voyage initiation in December 2024 and Panorama in January 2025. Q4 saw DT402 Phase 2a trial start in ASD, building pipeline momentum amid 99.7M shares outstanding as of February 2026. Cash position stood at $487.7M market value for non-affiliates as of June 30, 2025. No quarterly financials or capex detailed. Pipeline delays risk quarterly progress.
8-K
Cash $412M; Phase 3 enrolled
Definium Therapeutics reported full-year 2025 results on February 26, 2026, with cash at $411.6 million funding operations into 2028, up from $273.7 million after a $259 million equity raise. Emerge Phase 3 MDD trial fully enrolled; topline data due late 2Q 2026. Voyage GAD trial 80% enrolled. R&D expenses surged to $117.7 million, driving $183.8 million net loss.
8-K
Board adds Roger Adsett
Definium Therapeutics expanded its board from six to seven directors, appointing Roger Adsett effective January 29, 2026, with his term ending at the 2026 annual meeting. He'll earn $40,000 annually under the non-employee policy, plus an option for 50,000 common shares vesting over three years. No committee roles yet. Clean appointment, no related transactions.
8-K
Rebrand, $412M cash
Definium Therapeutics rebranded from MindMed on January 9, 2026, shifting to ticker DFTX on Nasdaq from January 13 while holding ~$412M in preliminary cash and equivalents as of December 31, 2025. This funds Phase 3 readouts for DT120 ODT in GAD and MDD through 2026. Cash runway extends into 2028. Figures preliminary, unaudited.
10-Q
Q3 FY2025 results
MindMed ramped R&D expenses 80% y/y to $31.0M in Q3 ended September 30, 2025, driven by MM120 GAD/MDD trials, pushing operating loss to $45.7M from $24.8M while net loss exploded to $67.3M from $13.7M on $22.5M warrant fair-value hit. Cash burned $88.6M YTD on ops (derived), leaving $20.0M cash plus $189.1M short-term investments against $40.4M credit facility due 2029. No revenue yet. Clinical burn accelerates smartly. Post-quarter $242.8M raise extends runway into 2028. Warrant volatility stings.
ANRO
Alto Neuroscience, Inc.
17.10+0.07
CING
Cingulate Inc.
3.87-0.28
CMND
Clearmind Medicine Inc.
2.62-0.10
CYBN
Cybin Inc.
6.66+0.00
DRUG
Bright Minds Biosciences Inc.
93.99+8.32
HYFT
MindWalk Holdings Corp.
1.68-0.11
MNOV
MediciNova, Inc.
1.48-0.04
NERV
Minerva Neurosciences, Inc
4.17+0.13
NMRA
Neumora Therapeutics, Inc.
1.85-0.11
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01